Vonafexor
As of the edition of 20 October 2026, Vonafexor is a small molecule: stopped in 2026; acts on NR1H4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 3, 1 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Digestive system; Inherited and neonatal; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Vonafexor.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR1H4 | Bile acid receptor | Q96RI1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 2 | 0 | 1 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Enyo Pharma | Lead sponsor of trials | 2019 to now |